EPZ5676: Potent and Selective DOT1L Inhibitor for MLL Leukemia Research

Executive Summary: EPZ5676 (SKU A4166) is a potent, selective inhibitor of DOT1L, exhibiting an IC50 of 0.8 nM and Ki of 80 pM for DOT1L enzymatic inhibition [APExBIO]. This compound demonstrates >37,000-fold selectivity over related methyltransferases, minimizing off-target effects [Anbazhagan et al., 2024]. EPZ5676 acts as a SAM-competitive inhibitor, inducing unique conformational changes in the DOT1L active site. In vivo, it causes complete regression of MLL-rearranged leukemia xenografts in rats, with no significant toxicity observed. The compound is foundational for dissecting H3K79 methylation and MLL-fusion gene regulation in acute leukemia research.

Biological Rationale

DOT1L (Disruptor of Telomeric Silencing 1-Like) is a histone methyltransferase that catalyzes methylation at lysine 79 of histone H3 (H3K79). H3K79 methylation is a critical epigenetic mark regulating gene expression, particularly in hematopoietic cells [Anbazhagan et al., 2024]. In MLL-rearranged leukemia, fusion proteins aberrantly recruit DOT1L, leading to abnormal H3K79 methylation and dysregulation of genes such as HOXA9 and MEIS1. This epigenetic dysregulation is a driver of leukemogenesis. Selective inhibition of DOT1L is thus a targeted strategy to suppress oncogenic gene expression in these malignancies. Unlike pan-methyltransferase inhibitors, DOT1L-selective agents minimize effects on other histone marks, reducing unintended cellular toxicity.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a competitive inhibitor of the S-adenosyl methionine (SAM) binding pocket of DOT1L. It binds with high affinity, inducing conformational changes that open a unique hydrophobic pocket beyond the SAM amino acid moiety [APExBIO]. This mechanism is distinct from other methyltransferase inhibitors, conferring remarkable selectivity. The inhibition is reversible and non-covalent. EPZ5676 does not inhibit methyltransferases such as CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, or WHSC1/1L1 at concentrations up to 30 μM. In cell models, EPZ5676 treatment leads to loss of H3K79 methylation, downregulation of MLL-fusion target genes, and induction of apoptosis in MLL-rearranged leukemia cells. The compound’s selectivity profile is confirmed by enzymatic assays and cellular methylation profiling.

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L enzymatic activity with an IC50 of 0.8 nM and Ki of 80 pM, as determined in biochemical assays (APExBIO, product page).
• Demonstrates >37,000-fold selectivity for DOT1L over CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1, confirmed by cross-enzyme profiling (Anbazhagan et al., 2024).
• In MV4-11 acute leukemia cells, EPZ5676 reduces cell viability with an IC50 of 3.5 nM after 4–7 days (APExBIO, product page).
• In vivo, intravenous administration (35–70 mg/kg/day for 21 days) in nude rats with MV4-11 xenografts results in complete tumor regression without significant toxicity or weight loss (APExBIO, product page).
• EPZ5676 shows robust H3K79 methylation inhibition and downregulation of MLL target genes in preclinical leukemia models (KDM2A.com, extends mechanistic context).

Applications, Limits & Misconceptions

EPZ5676 is used primarily for epigenetic mechanistic studies, biochemical enzyme inhibition assays, and antiproliferative assays in leukemia cell lines. It is particularly valuable for dissecting the role of H3K79 methylation in MLL-rearranged leukemias. The compound is not a general cytotoxic agent and lacks efficacy in cancers without DOT1L-dependency or MLL rearrangements. Unlike pan-methyltransferase inhibitors, EPZ5676 does not target HDACs or other epigenetic regulators, as confirmed by the selectivity profiling presented in Anbazhagan et al. (2024). Its effectiveness in solid tumors or in non-MLL hematologic malignancies is unproven and not supported by current preclinical evidence.

Common Pitfalls or Misconceptions

• EPZ5676 does not inhibit HDACs or impact histone acetylation directly; its effect is limited to H3K79 methylation.
• Efficacy is largely restricted to MLL-rearranged leukemias; non-MLL cancers generally do not respond.
• The compound is insoluble in water and requires DMSO or ethanol (with ultrasonic assistance) for stock solution preparation.
• Long-term storage of solutions at room temperature leads to loss of potency; -20°C is required.
• Not suitable for in vivo studies in species with rapid DOT1L turnover unless dosing is adjusted based on pharmacokinetic parameters.

For a deeper mechanistic comparison, see DOT1L Inhibitor EPZ-5676: Pioneering Mechanistic Precision (this article provides updated clinical benchmarks beyond the original mechanistic review).

Workflow Integration & Parameters

EPZ5676, supplied as a solid, has a molecular weight of 562.71. It is soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (ultrasonicated), but insoluble in water. For biochemical assays, prepare stock solutions in DMSO and store at -20°C. Avoid repeated freeze-thaw cycles. For cell culture, dilute stocks into culture medium immediately before use. The recommended working concentration for cellular antiproliferative assays is 1–10 nM, with 4–7 days of exposure for optimal effect in MV4-11 cells. For in vivo models, intravenous dosing at 35–70 mg/kg/day for 21 days has shown robust efficacy without notable toxicity. To maintain compound integrity, avoid long-term storage of diluted solutions.

For troubleshooting, see DOT1L Inhibitor EPZ-5676 (SKU A4166): Data-Driven Best Practices, which offers protocol optimization guidance not detailed here.

Conclusion & Outlook

EPZ5676, available from APExBIO, stands as the gold-standard DOT1L inhibitor for epigenetic research in MLL-rearranged leukemia models. Its high selectivity, nanomolar potency, and validated in vivo efficacy enable precise interrogation of H3K79 methylation and MLL-fusion gene regulation. While its clinical translation remains under investigation, EPZ5676 has defined the paradigm for selective epigenetic inhibition. Researchers are encouraged to combine EPZ5676 with orthogonal tools for comprehensive mechanistic studies, and to consult recent reviews for updates on immune-epigenetic applications (see here for emerging roles in fibrosis and cancer immunology; this article adds detail on leukemia-specific selectivity).